Information Provided By: 
Fly News Breaks for August 1, 2018
NLNK
Aug 1, 2018 | 07:43 EDT
As previously reported, Stifel analyst Stephen Willey downgraded NewLink Genetics to Hold from Buy, stating that the visibility going forward is increasingly limited given the limited amount of indoximod data generated to date in indications management now intends to pursue. He believes NewLink's strategic approach to AML carries substantial development, regulatory and commercial risk, Willey tells investors after the company announced the implementation of a restructuring plan. He lowered his price target on NewLink shares to $4 from $8.
News For NLNK From the Last 2 Days
There are no results for your query NLNK
